Clinical Trial Search

Primary: Generalized Anxiety Disorder-7 (Gad-7) — 14.86; 12.88; 8.33; 7.62 units on a scale

Primary: Measured MEMS Adherence- Number of Days With a Correct Number of Doses Taken — 15.14; 20.22 Days

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Statin Adherence — 86; 85; 86; 85 percentage of correct statin doses

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001

Primary: Data on Prescription Drug Renewals, Appointment Compliance and Medication Taking (e.g. Physician Notes) — 150; 152 participants

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Statin Adherence — 79; 84; 80 percentage of correct statin doses

Primary: Medication Adherence — 93.08; 89.52 percentage of doses recorded as taken — p=0.28

Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken

Primary: Adherence to the Intermittent Fasting Regimen, Captured Via Daily Text Message, Over 18 Weeks, Expressed in Days Per Week — 4.7; 5.4 days per week

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Medication Adherence at 1 Month — 11.83; 10.20; 9.33 score on a scale

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: Percentage of Participants Who Were Compliant With Statin Treatment — 86.7 Percentage of participants

Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation

Primary: Distribution of Participants Responses as Regards DSMQ Glucose Management Domain — 13; 56; 39; 45 Participants

Primary: Number of Sessions Attended — 7.70; 4.98 sessions — p=0.24

Primary: Acceptability of Intervention and Study Procedures — 17; 14; 17 Participants

Primary: Medication Adherence — 21.6; 23.8 score on a scale

Primary: Medication Possession Ratio at Baseline — 65.0 percentage of medication possession

Primary: Rate of Participant Retention — 23; 29; 18; 10 Participants

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days

Primary: Nightly Adherence — 4.83; 5.82; 4.82; 4.60 hours